REFERENCES

1. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 2017;317:1338-48.

2. Harari A, Singh RK. Increased rates of advanced thyroid cancer in California. J Surg Res 2016;201:244-52.

3. Davidson CD, Carr FE. Review of pharmacological inhibition of thyroid cancer metabolism. J Cancer Metastasis Treat 2021;7:45.

4. Nagayama Y. Autophagy and thyroid cancer. J Cancer Metastasis Treat 2021;7:6.

5. Lee WK, Cheng SY. Targeting transcriptional regulators for treatment of anaplastic thyroid cancer. J Cancer Metastasis Treat 2021;7:27.

6. Quartuccio N, Rubello D. Role of ¹⁸F-FDG PET/CT in detection of hematogenous metastases of advanced differentiated thyroid carcinoma: a systematic review and meta-analysis. J Cancer Metastasis Treat 2021;7:14.

7. Corn S, Mitmaker E, Tabar R, Ciarallo A, How J. Incidental thyroid uptake on PET scanning: epidemiology, clinical significance, and management challenge. J Cancer Metastasis Treat 2021;7:41.

8. Matrone A, Gambale C, Prete A, et al. Systemic treatment of advanced, metastatic, medullary thyroid carcinoma. J Cancer Metastasis Treat 2021;7:23.

9. Izkhakov E, Keinan-boker L, Stern N. Cardiovascular morbidity and mortality as a confounder of prognosis in thyroid cancer. J Cancer Metastasis Treat 2021;7:24.

10. Priya S, Garg S, Dandekar M. Intraoperative monitoring of the recurrent laryngeal nerve in surgeries for thyroid cancer: a review. J Cancer Metastasis Treat 2021;7:70.